1
Participants
Start Date
May 15, 2021
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
BNT162b2 BA.4/5 bivalent
Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
XBB.1.5-adapted vaccinated
Vaccinated with XBB.1.5-adapted vaccine
Kaiser Permanente Southern California, Pasadena
Lead Sponsor
Pfizer
INDUSTRY